BPC-157
A synthetic 15 amino acid peptide from a gastric protein sequence, studied mainly in rodent injury models with very little human data.
Peptide research index
Plain-English research profiles of the peptides and related compounds that come up most in the literature: what each one is, where it came from, what published studies have actually examined, and what is still unknown. Every profile cites its sources. Nothing here is medical advice or usage guidance.
13 profiles
CJC-1295
A synthetic GHRH analog studied in two forms: with DAC (long acting, small human trials) and without DAC (short acting, little human data).
Epithalon
Synthetic four amino acid peptide studied mainly by one St. Petersburg group for effects on telomerase and aging in cells and rodents.
GHK-Cu
A copper-binding tripeptide found in human plasma, studied in cell and wound models and used as a cosmetic ingredient.
Ipamorelin
A synthetic ghrelin receptor agonist that was selective for GH release in animals; its one human efficacy trial did not beat placebo.
Melanotan II
An unapproved synthetic melanocortin agonist studied briefly in the 1990s; its unregulated use is tied to case reports of serious harm.
NAD+
A coenzyme, not a peptide, central to energy metabolism. Levels fall with age in studies, and raising them is an active area of aging research.
Retatrutide
An investigational single peptide that activates the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and now in phase 3 trials.
Selank
Synthetic seven amino acid tuftsin analog, a registered medicine in Russia, studied mostly by Russian groups for anxiety-related effects.
Semaglutide
A long-acting GLP-1 receptor agonist developed by Novo Nordisk and studied in large trial programs on glucose, body weight and cardiovascular outcomes.
Semax
Synthetic seven amino acid ACTH fragment analog, a registered medicine in Russia, studied mostly by Russian groups for brain effects.
TB-500 (Thymosin Beta-4)
A synthetic fragment marketed in reference to thymosin beta-4, a 43 amino acid protein studied in wound, eye and heart research.
Tirzepatide
A single peptide that activates both the GIP and GLP-1 receptors, developed by Eli Lilly and studied in the SURPASS and SURMOUNT trial programs.